Grant: CIHR New Investigator
McGill University
$300,000.00
Leukodystrophy: A Translational Research Program
EF 2015-16
Résumé
Leukodystrophies are a group of rare genetic diseases affecting previously healthy children and leading to progressive disabilities and death over months to years. Unfortunately, no curative treatment is available. It is estimated that 30-50% of patients remain without a precise diagnosis despite multiple tests. The first step to discover a treatment is to understand the causes of the diseases and therefore, to identify the causal genes. Leukodystrophies are characterized by abnormal white matter (myelin) of the brain. Myelin is responsible for the insulation of brain cells (neurons), allowing fast electric conduction in the nervous system. Leukodystrophies are classified as hypomyelinating (lack of myelin formation) and non-hypomyelinating (abnormal myelin maintenance) based on features seen in brain scans. My research program focuses on hypomyelinating leukodystrophies, and more specifically on one disorder called POLR3-related or 4H leukodystrophy. Children with this disease develop progressive difficulties to walk, talk, swallow and see (myopia). 4H is caused by mutations in 3 genes that are important for survival of the cells. Using 4H as my primary disease of interest, my comprehensive research program aims at describing these diseases, including their evolution over time and their impact on patients and their families, finding causal genes and explaining how mutations lead to disease (pathophysiology) in order to improve medical care for the patients and families, find new treatments and prepare for the upcoming clinical trials.
Programme
CIHR New Investigator
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
340639
Name
Bernard Geneviève
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Clinical
Prcname2
Health Professional Awards - New Investigators
Projecttitle
Leukodystrophy: A Translational Research Program
Programtype2
Salary Programs
Orgnameinp2
McGill University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
CIHR New Investigator
Keyworddelim
Clinical Characterization; Genetic Characterization; Hypomyelinating Leukodystrophies; Leukodystrophies; Mri Characterization; Pathophysiological Characterization; Polr3-Related (4h) Leukodystrophy
Abstract
Leukodystrophies are a group of rare genetic diseases affecting previously healthy children and leading to progressive disabilities and death over months to years. Unfortunately, no curative treatment is available. It is estimated that 30-50% of patients remain without a precise diagnosis despite multiple tests. The first step to discover a treatment is to understand the causes of the diseases and therefore, to identify the causal genes. Leukodystrophies are characterized by abnormal white matter (myelin) of the brain. Myelin is responsible for the insulation of brain cells (neurons), allowing fast electric conduction in the nervous system. Leukodystrophies are classified as hypomyelinating (lack of myelin formation) and non-hypomyelinating (abnormal myelin maintenance) based on features seen in brain scans. My research program focuses on hypomyelinating leukodystrophies, and more specifically on one disorder called POLR3-related or 4H leukodystrophy. Children with this disease develop progressive difficulties to walk, talk, swallow and see (myopia). 4H is caused by mutations in 3 genes that are important for survival of the cells. Using 4H as my primary disease of interest, my comprehensive research program aims at describing these diseases, including their evolution over time and their impact on patients and their families, finding causal genes and explaining how mutations lead to disease (pathophysiology) in order to improve medical care for the patients and families, find new treatments and prepare for the upcoming clinical trials.
Competitiondate
201512
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Bernard, Geneviève
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~